Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of DTPa-IPV/Hib primary and booster vaccination in healthy infants in Russia
2013-005577-43Phase 3
- Sponsor
- GSK
- Start
- Aug 2016
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of acthib + dpt-ipv in diphtheria, Tetanus, pertussis and 2 more, sponsored by GSK. Primary endpoint: Seroprotection against diphtheria and tetanus after primary vaccination.
02
Drugs
acthib + dpt-ipv
03
Conditions
diphtheriaTetanuspertussispoliomyelitisHaemophilus influenzae type b disease (Hib)
Beyond the preview
Go deeper on 2013-005577-43.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-005577-43.